179 related articles for article (PubMed ID: 35444940)
1. Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and
Ye W; He L; Su L; Zheng Z; Ding M; Ye S
Front Oncol; 2022; 12():868654. PubMed ID: 35444940
[TBL] [Abstract][Full Text] [Related]
2. Significant role of savolitinib in a case of advanced gastric cancer with abnormal mesenchymal-epithelial transition factor (MET): A case report.
He X; An G
Medicine (Baltimore); 2022 Dec; 101(48):e32072. PubMed ID: 36482562
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
4. Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report.
Yan N; Zhang Z; Guo S; Shen S; Li X
Front Med (Lausanne); 2023; 10():1130012. PubMed ID: 37293311
[TBL] [Abstract][Full Text] [Related]
5. Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1-positive patient with advanced non-small cell lung cancer.
Xiong Y; Cao Q; Guo Y; Liu X; Zhu X; Dai B; Zhu B
Front Pharmacol; 2023; 14():1089184. PubMed ID: 36817157
[TBL] [Abstract][Full Text] [Related]
6. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
[TBL] [Abstract][Full Text] [Related]
7. [Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib].
Zhang L; Wang YS; Lin LZ; Yu YF; Lu S
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):298-312. PubMed ID: 37078211
[TBL] [Abstract][Full Text] [Related]
8. Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring
Han S; Fang J; Lu S; Wang L; Li J; Cheng M; Ren Y; Su W
Onco Targets Ther; 2019; 12():7323-7328. PubMed ID: 31564914
[TBL] [Abstract][Full Text] [Related]
9. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
[TBL] [Abstract][Full Text] [Related]
11. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Yang JJ; Fang J; Shu YQ; Chang JH; Chen GY; He JX; Li W; Liu XQ; Yang N; Zhou C; Huang JA; Frigault MM; Hartmaier R; Ahmed GF; Egile C; Morgan S; Verheijen RB; Mellemgaard A; Yang L; Wu YL
Invest New Drugs; 2021 Apr; 39(2):477-487. PubMed ID: 33052556
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in
Frigault MM; Markovets A; Nuttall B; Kim KM; Park SH; Gangolli EA; Mortimer PGS; Hollingsworth SJ; Hong JY; Kim K; Kim ST; Barrett JC; Lee J
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923890
[TBL] [Abstract][Full Text] [Related]
13. Role of savolitinib in advanced gastric adenocarcinoma with meningeal carcinomatosis and cerebellar metastasis: A case report.
Weng ZY; Huang WY; Shi BK; Pan JJ
World J Clin Cases; 2024 May; 12(15):2636-2641. PubMed ID: 38817213
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity.
Jones RDO; Grondine M; Borodovsky A; San Martin M; DuPont M; D'Cruz C; Schuller A; Henry R; Barry E; Castriotta L; Anjum R; Petersson K; Sahota T; Ahmed GF
Br J Pharmacol; 2021 Feb; 178(3):600-613. PubMed ID: 33125717
[TBL] [Abstract][Full Text] [Related]
15. Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib.
Zhang L; Wang Y; Lin L; Yu Y; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231216089. PubMed ID: 38145112
[TBL] [Abstract][Full Text] [Related]
16. Savolitinib: A Promising Targeting Agent for Cancer.
Lee TS; Kim JY; Lee MH; Cho IR; Paik WH; Ryu JK; Kim YT; Lee SH
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835402
[TBL] [Abstract][Full Text] [Related]
17. Response to Savolitinib in a Patient with Advanced Poorly Differentiated Lung Carcinoma Positive for a Novel EML4-MET Gene Fusion.
Ouyang G; Shu P; Xue Y; Luo F; Li Y
Onco Targets Ther; 2024; 17():79-84. PubMed ID: 38313385
[TBL] [Abstract][Full Text] [Related]
18. Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review.
Zhou K; Liu Y; Zhu H
Front Oncol; 2023; 13():1254026. PubMed ID: 38023194
[TBL] [Abstract][Full Text] [Related]
19. Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:
Safety, Efficacy, and Biomarkers.
Wang Y; Liu T; Chen G; Gong J; Bai Y; Zhang T; Xu N; Liu L; Xu J; He J; Liu Y; Zhang L; Jiang D; Wang M; Chang J; Li W; Bai C; Zhou J; Wang J; Ren Y; Zhang L; Su W; Liu B; Shen L
Oncologist; 2022 Apr; 27(5):342-e383. PubMed ID: 35445725
[TBL] [Abstract][Full Text] [Related]
20. Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report.
Zhang Y; Zhang H; Wang H; Zeng J; Zhang B; Zhou N; Zu L; Song Z; Wang C; Xu S
Front Oncol; 2022; 12():968030. PubMed ID: 36176406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
